Compare Incyte Corporation (INCY) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Texas Instruments Incorporated — how do they compare? Incyte Corporation trades at $113.15 (market cap $22.85B), while Texas Instruments Incorporated trades at $284.1 (market cap $263.20B). The key difference: Texas Instruments Incorporated is far larger — about 11.5× Incyte Corporation's market cap, and Texas Instruments Incorporated pays a 2.11% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Texas Instruments Incorporated for 76 Days on average.
| INCY | TXN | |
|---|---|---|
Market Cap | $22.85B | $263.20B |
Volume | 1,927,029 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $129.93 | $332.35 |
52-Week Low | $83.80 | $153.33 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $18.35B | $270.25B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Texas Instruments (TXN) trades at $288.94, down 2.82% on the day, amid a broader semiconductor sell-off. The stock maintains a bullish technical outlook with strong moving average signals and key support at $286. Fundamentally, revenue and earnings are recovering, with Q2 2026 EPS beating expectations at $2.14 versus $1.91, driven by data center sales growth and margin expansion. The company's net income margin stands at 31.11%, with robust cash flow from operations of $7.15 billion in 2025.
The outlook for TXN is positive, supported by accelerating data center demand, AI infrastructure investments, and a consensus price target of $325 implying 12% upside. Risks include premium valuation with a P/E of 43.8 and rising debt-to-asset ratio of 40.61% in 2025. Analyst sentiment is bullish with 47.69% buy ratings, though competitive pressures and cyclical semiconductor demand pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
